Express News | Personalis Provides Dial-in and Updated Date for Asco Highlights Conference Call
ASCO Data Highlights NeXT Personal Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis will host a webinar call on June 19th, 2024 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time to present ASCO highlights from the conference Personalis, Inc. (NASDAQ:PSNL) announced today that data
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Tempus Announces the Clinical Launch of Its MRD Testing Portfolio
xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoringCHICAGO--(BUSINESS WIRE)--Tempus, a leader in artifi
Express News | Personalis Announces Tempus Begins Commercialization Of NeXT Personal, An Ultra-Sensitive Liquid Biopsy Assay For Detecting Minimal Residual Disease And Cancer Recurrence
Express News | Personalis Announces Start of Cancer Mrd Testing Commercialization Collaboration With Tempus
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $4
Lake Street analyst Thomas Flaten maintains $Personalis(PSNL.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.1% and a tota
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal whole
Express News | Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
4 Analysts Have This To Say About Personalis
Personalis (NASDAQ:PSNL) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustra
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
Personalis (PSNL) Receives a Buy From Lake Street
Express News | Personalis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued Q2 Revenue Guidance Above Estimates
Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Revolution Medicines (RVMD) and Personalis (PSNL)
Personalis Price Target Maintained With a $3.50/Share by Needham
Personalis Price Target Maintained With a $3.50/Share by Needham
Express News | Needham Reiterates Buy on Personalis, Maintains $3.5 Price Target
Personalis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 105.88% Needham → $3.5 Reiterates Buy → Buy 04/30/2024 135.29% Lake Street → $4 Initiates Cover
Buy Rating Affirmed for Personalis Amid Strong Financial Performance and Strategic Growth Prospects
No Data